Bridgend, Wales – July 1, 2025 – MPM Health today announces significant leadership transitions and a strategic rebranding initiative, positioning the company for its next phase of growth and innovation in biosciences.

Effective today, Stephen Pickett will transition from Non-Executive Director to Chief Executive Officer. Concurrently, Nigel Pickett will move from Chief Executive Officer to Chief Strategy Officer. These changes reflect a strategic realignment of leadership to best leverage individual strengths and drive the company’s ambitious goals.

Nigel Pickett, who has led MPM Health since its incorporation in 2020, shared his thoughts on the transition:

“It’s been an incredibly rewarding journey building MPM Health from the ground up. I’ve thoroughly enjoyed my time as CEO, but I believe now is the right moment for new energy and fresh leadership to guide the company into its next chapter. I’m excited to transition to Chief Strategy Officer, where I’ll focus on charting our long-term strategic course and supporting Stephen as he leads MPM Health to even greater heights.”

As we prepare for the unveiling of our new brand, MPM Health is excited to share key advancements:

• Refined Focus: MPM Health is sharpening its focus on molecular and multiomic analysis and diagnostics within the biosciences. Our aim is to develop truly innovative platforms that will drastically cut the time, cost, and risk associated with DNA sequencing, infectious disease, and pathogen diagnoses. These advancements are poised to significantly enhance diagnostic capabilities and unlock new avenues for personalised treatment.
• Molecular Omics Platform: MPM Health is nearing completion of the development its first molecular omics platform for testing.
• Deepened Collaboration with SiGenex: Our collaboration with SiGenex has intensified, with SiGenex actively preparing to test its sample to report benchtop sequencing platform with the direct support of MPM Health.

In anticipation of these significant milestones, and to align with a refined vision for the business, the executive team has made the decision to rebrand MPM Health. Details of our new brand will be unveiled in the coming weeks. Furthermore, the board has been restructured to guide the company through the next five years, and the executive team’s roles have been realigned to optimise their expertise, capability, and experience. We are also actively recruiting new talent to fill key positions.

Stephen Pickett stated:

“I am incredibly excited to step into the role of CEO at such a pivotal time for MPM Health. Our refined focus on molecular and multiomic analysis and diagnostics, coupled with the revolutionary potential of our platforms, positions us to make a profound impact on the biosciences within multiple industries. I look forward to leading MPM Health through this exciting new chapter, building on Nigel’s strong foundation, and bringing our transformative technologies to market. I and the board are ever grateful for his leadership over the last 5 years and look forward to his continued guidance in his new role going forwards.”

This comprehensive strategic evolution, encompassing leadership changes, a refined strategic focus, rebranding, and operational alignments, marks an exciting new chapter for MPM Health as we prepare to revolutionise the molecular and genetic testing landscape.

About MPM Health

MPM Health is a South Wales-based healthcare solutions company focused on delivering innovative diagnostic technologies across the UK and Europe. Founded in 2020, the company partners with global innovators to deploy cutting-edge platforms, including automated bench-top sequencing platform and the Molecular Diagnostics Platform (MDP), to healthcare providers. Operating on a ‘Sequencing as a Service’ model, MPM Health provides this advanced equipment with no upfront capital cost, aiming to make sophisticated diagnostics more affordable and accessible. 

Originally founded to address health disparities in regions such as the South Wales Valleys, MPM Health takes its name from original founders Midgley, Pickett, and Marsh. Now led by Stephen, Nigel, and Simon Pickett, along with Dr. Luke Midgley, the company is focused on advancing pathogen detection, drug resistance testing and molecular diagnostics for oncology. In 2025, it will begin independent evaluations of SiGenex’s point of care sequencing platform at leading UK institutions, with planned regulatory submissions to the MHRA, CE, and FDA.

About SiGenex

SiGenex is building a global, decentralised network for genetic testing and genomic intelligence. Its proprietary platform integrates AI-driven sample processing, automated sequencing, and advanced bioinformatics to deliver rapid, actionable insights at the point of care. By streamlining workflows, reducing turnaround times, and lowering costs, SiGenex empowers clinicians worldwide with timely data to inform critical therapeutic decisions. The company operates internationally, with facilities at Oxford University’s Bioescalator, a development hub in Kuala Lumpur, and a strategic base in Boston. In the UK, SiGenex has partnered with MPM Health to lead deployment and regional adoption of its technology.